- Home
- CDLX
CDLX
Cardlytics Inc.
as of 03-19-2026 3:59pm EST
Cardlytics Inc operates an advertising platform within financial institutions' digital channels, which include online, mobile, email, and various real-time notifications. The company operates through segments namely, Cardlytics platform in the U.S. and U.K. and the Bridg platform. The Cardlytics platform segment which generates key revenue, operates a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels. The Bridg platform generates revenue through the sale of subscriptions to the cloud-based customer-data platform and the delivery of professional services like implementation, onboarding, and technical support. The company receives maximum revenue from the United States.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | ATLANTA |
| Market Cap: | 69.7M | IPO Year: | 2018 |
| Target Price: | $2.25 | AVG Volume (30 days): | 643.5K |
| Analyst Decision: | Hold | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.95 | EPS Growth: | 50.13 |
| 52 Week Low/High: | $0.67 - $3.28 | Next Earning Date: | 03-04-2026 |
| Revenue: | $233,273,000 | Revenue Growth: | -16.18% |
| Revenue Growth (this year): | -4.18% | Revenue Growth (next year): | 46.84% |
| P/E Ratio: | -0.37 | Index: | N/A |
| Free Cash Flow: | 8.8M | FCF Growth: | N/A |
AI-Powered CDLX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Cardlytics Inc. (CDLX)
Chief Executive Officer
Avg Cost/Share
$0.93
Shares
45,159
Total Value
$41,817.23
Owned After
659,644
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$0.90
Shares
52,049
Total Value
$46,948.20
Owned After
659,644
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$1.17
Shares
5,807
Total Value
$6,794.19
Owned After
659,644
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$1.17
Shares
8,607
Total Value
$10,070.19
Owned After
201,159
SEC Form 4
Chief Legal & Privacy Officer
Avg Cost/Share
$1.17
Shares
6,253
Total Value
$7,316.01
Owned After
122,862
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Gupta Amit | CDLX | Chief Executive Officer | Feb 18, 2026 | Sell | $0.93 | 45,159 | $41,817.23 | 659,644 | |
| Gupta Amit | CDLX | Chief Executive Officer | Feb 17, 2026 | Sell | $0.90 | 52,049 | $46,948.20 | 659,644 | |
| Gupta Amit | CDLX | Chief Executive Officer | Jan 5, 2026 | Sell | $1.17 | 5,807 | $6,794.19 | 659,644 | |
| DeSieno Alexis | CDLX | Chief Financial Officer | Jan 5, 2026 | Sell | $1.17 | 8,607 | $10,070.19 | 201,159 | |
| Lynton Nicholas Hollmeyer | CDLX | Chief Legal & Privacy Officer | Jan 5, 2026 | Sell | $1.17 | 6,253 | $7,316.01 | 122,862 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Mar 4, 2026 · 100% conf.
Q4 2025 Earnings
8-K SELLMar 4, 2026 · 100% conf.
1D
-20.02%
$0.72
Act: -9.36%
5D
-18.42%
$0.73
20D
-18.96%
$0.73
cdlx-202603040001666071false00016660712026-03-042026-03-04
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2026
CARDLYTICS, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware001-3838626-3039436 (State or other jurisdiction of incorporation or organization)(Commission File Number)(I.R.S. Employer Identification No.) 675 Ponce de Leon Avenue NE, Suite 4100AtlantaGeorgia30308 (Address of principal executive offices, including zip code) (888)798-5802 (Registrant's telephone, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:
Title of each classTrading symbolName of each exchange on which registered Common StockCDLXThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On March 4, 2026, the Company issued a press release announcing its financial results for the quarter and year ended December 31, 2025, as well as information regarding a conference call to discuss these financial results and the Company’s recent corporate highlights. The Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included in this Item 2.02 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits
Exhibit Exhibit Description 99.1 Press release dated March 4, 2026
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Cardlytics, Inc.
Date:March 4, 2026 By:/s/ David Evans David Evans Chief Financial Officer (Principal Financial and Accounting Officer)
2025 Q3 Q3 2025 Earnings
8-K Nov 5, 2025
Q3 2025 Earnings
8-KNov 5, 2025
cdlx-202511050001666071false00016660712025-11-052025-11-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2025
CARDLYTICS, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware001-3838626-3039436 (State or other jurisdiction of incorporation or organization)(Commission File Number)(I.R.S. Employer Identification No.) 675 Ponce de Leon Avenue NE, Suite 4100AtlantaGeorgia30308 (Address of principal executive offices, including zip code) (888)798-5802 (Registrant's telephone, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:
Title of each classTrading symbolName of each exchange on which registered Common StockCDLXThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:
ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On November 5, 2025, Cardlytics, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2025, as well as information regarding a conference call to discuss these financial results and the Company’s recent corporate highlights. The Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included in this Item 2.02 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits
Exhibit Exhibit Description 99.1 Press release dated November 5, 2025
104The cover page from Cardlytics, Inc.’s Form 8-K filed on November 5, 2025, formatted in Inline XBRL.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Cardlytics, Inc.
Date:November 5, 2025By:/s/ Alexis DeSieno Alexis DeSieno Chief Financial Officer (Principal Financial and Accounting Officer)
2025 Q2 Q2 2025 Earnings
8-K Aug 6, 2025
Q2 2025 Earnings
8-KAug 6, 2025
cdlx-202508060001666071false00016660712025-08-062025-08-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025
CARDLYTICS, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware001-3838626-3039436 (State or other jurisdiction of incorporation or organization)(Commission File Number)(I.R.S. Employer Identification No.) 675 Ponce de Leon Avenue NE, Suite 4100AtlantaGeorgia30308 (Address of principal executive offices, including zip code) (888)798-5802 (Registrant's telephone, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:
Title of each classTrading symbolName of each exchange on which registered Common StockCDLXThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:
ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On August 6, 2025, Cardlytics, Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2025, as well as information regarding a conference call to discuss these financial results and the Company’s recent corporate highlights. The Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included in this Item 2.02 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits
Exhibit Exhibit Description 99.1 Press release dated August 6, 2025
104The cover page from Cardlytics, Inc.’s Form 8-K filed on August 6, 2025, formatted in Inline XBRL.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Cardlytics, Inc.
Date:August 6, 2025By:/s/ Alexis DeSieno Alexis DeSieno Chief Financial Officer (Principal Financial and Accounting Officer)
Compare CDLX vs Leading Stocks
See how CDLX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CDLX Cardlytics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.